| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.35 | 2e-20 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-07 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.15 | 3e-06 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.14 | 3e-06 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.14 | 1e-05 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.12 | 2e-05 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.14 | 9e-05 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0001 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0001 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | 0.26 | 0.0002 |